A 62-year-old postmenopausal woman presents to the clinic with a 2-month history of postcoital bleeding. Which assessment finding would be most concerning for endometrial cancer?

Clinical Reasoning for the NCLEX-RN

This question asks you to identify the most concerning finding for endometrial cancer in a postmenopausal woman with postcoital bleeding. While postcoital bleeding is a classic symptom of cervical pathology, in a postmenopausal woman, any abnormal bleeding must prompt a thorough evaluation of the uterine cavity. The correct answer is option 3 because it directly links a high-risk symptom with a specific, objective imaging threshold that mandates further investigation.

Analysis of the Correct Answer (Option 3)
Postmenopausal bleeding is the cardinal symptom of endometrial cancer, and a finding of endometrial thickness greater than 4mm on transvaginal ultrasound is a well-established threshold for concern. In a postmenopausal woman not on hormone therapy, the endometrium should be thin and atrophic. A thickened endometrial stripe above 4mm is highly suspicious for hyperplasia or carcinoma and necessitates an endometrial biopsy for definitive diagnosis [1,4]. This combination of the classic symptom and an abnormal imaging finding represents the highest predictive value for malignancy in the initial workup.

Analysis of Incorrect Answers

Option 1: Cervical dysplasia found on a routine Pap smear is a screening finding for cervical cancer and its precursors, not endometrial cancer. While a Pap smear can occasionally detect shed endometrial cells, it is an insensitive and nonspecific test for endometrial pathology. Attributing postcoital bleeding solely to cervical dysplasia without evaluating the endometrium would be a critical clinical error in a postmenopausal patient ^[1].

Option 2: A first-degree relative with breast cancer is a significant piece of family history that raises suspicion for a hereditary cancer syndrome, such as Lynch syndrome or a BRCA mutation, which can increase the risk for both breast and endometrial cancers. However, this is a risk factor, not a direct assessment finding. It increases the patient's lifetime risk but does not provide immediate diagnostic information about the current bleeding episode. The physical and imaging findings take priority in the acute diagnostic workup.

Option 4: An elevated serum CA-125 level is a tumor marker more commonly associated with epithelial ovarian cancer. It is not a sensitive or specific screening or diagnostic tool for early-stage endometrial cancer. Levels can be elevated in a variety of benign conditions, including endometriosis, pelvic inflammatory disease, and even pregnancy. A normal CA-125 does not rule out endometrial cancer, and an elevated level alone is not the most concerning or specific finding for this diagnosis ^[1].

Pathophysiology and Clinical Workup Integration
The clinical challenge, as highlighted in the literature, is that while abnormal uterine bleeding is the most common presenting symptom of endometrial cancer, the underlying prevalence of malignancy is low (around 3%) ^[3]. This creates a diagnostic dilemma where clinicians must efficiently triage patients. The initial step is a transvaginal ultrasound to measure endometrial thickness. The >4mm threshold is used because of its high sensitivity for detecting endometrial pathology, ensuring that cases are not missed, even though its specificity is limited ^[3]. A thin, distinct endometrial echo of 4mm or less has a very high negative predictive value for endometrial cancer, effectively ruling it out in most cases. When the threshold is exceeded, the standard of care is to proceed to hysteroscopy and endometrial biopsy for a definitive histological diagnosis, which remains the gold standard ^[4]. This structured approach—symptom recognition, ultrasound-based triage, and tissue diagnosis—is the core of safe and effective nursing and medical management.